AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
73.76
+0.23 (0.31%)
At close: Sep 26, 2025, 4:00 PM EDT
73.75
-0.01 (-0.01%)
After-hours: Sep 26, 2025, 7:45 PM EDT
AstraZeneca Employees
AstraZeneca had 92,900 employees as of December 31, 2024. The number of employees increased by 3,000 or 3.34% compared to the previous year.
Employees
92,900
Change (1Y)
3,000
Growth (1Y)
3.34%
Revenue / Employee
$608,192
Profits / Employee
$89,290
Market Cap
228.75B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
Dec 31, 2013 | 51,500 | -200 | -0.39% |
Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
Dec 31, 2007 | 67,400 | 600 | 0.90% |
Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
AZN News
- 2 days ago - A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff - Seeking Alpha
- 2 days ago - AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices - WSJ
- 2 days ago - AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions - Business Wire
- 2 days ago - AstraZeneca to cut some direct-to-patient US drug prices after Trump demand - Reuters
- 3 days ago - AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors - Seeking Alpha
- 4 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer - Business Wire
- 6 days ago - European Advisory Panel Recommends Two AstraZeneca Drugs For Approval - Benzinga
- 6 days ago - SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer - PRNewsWire